Clinical Trials Browser

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

Metastatic Gastroesophageal Junction Adenocarcinoma

Stomach Neoplasms

Advanced Intrahepatic Cholangiocarcinoma

Advanced Solid Tumor

Pancreatic Cancer Metastatic

Pancreatic Cancer Resectable

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Pancreatic Neoplasms

Pancreatic Neoplasms

Colorectal Cancer Metastatic

Turcot syndrome, Rectal Neoplasms

Advanced Solid Tumours

Locally Advanced Cervical Carcinoma

Colorectal Neoplasms

Stomach Neoplasms

Locally Advanced or Metastatic Solid Tumors

Advanced Biliary Tract Cancer

Melanoma, Neoplasms

Carcinoma, Hepatocellular

Multiple Primary Lung Cancer

Stomach Neoplasms

Stomach Neoplasms

Adenocarcinoma

Clinical Trials

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma

: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

CISPD-7

mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer

Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer

IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC

Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer

Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer

Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer